COST-EFFECTIVENESS OF INDIVIDUALIZING GLYCEMIC GOALS FOR US ADULTS WITH TYPE 2 DIABETES

被引：0
|
作者：
Laiteerapong, Neda [1 ]
Cooper, Jennifer [1 ]
Naylor, Rochelle N. [1 ]
Huang, Elbert S. [1 ]
机构：
[1] Univ Chicago, Chicago, IL 60637 USA
来源：
JOURNAL OF GENERAL INTERNAL MEDICINE | 2016年 / 31卷
关键词：
D O I：
暂无
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
引用
收藏
页码：S169 / S170
页数：2
相关论文
共 50 条
  • [21] Pioglitazone versus rosiglitazone treatment in patients with type 2 diabetes and dyslipidemia: cost-effectiveness in the US
    Tunis, Sandra L.
    Minshall, Michael E.
    Charles, Meaghan St.
    Pandya, Bhavik J.
    Baran, Robert W.
    CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (11) : 3085 - 3096
  • [22] COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN VERSUS ALBIGLUTIDE AMONG INDIVIDUALS WITH TYPE 2 DIABETES IN THE US
    Alshehri, A.
    Alkhuzam, K.
    Niu, S.
    Jiao, T.
    Zhang, Y.
    Shao, H.
    VALUE IN HEALTH, 2022, 25 (07) : S373 - S373
  • [23] Individualizing Target Goals and Treatment in Patients with Type 2 Diabetes
    Shaughnessy, Allen F.
    AMERICAN FAMILY PHYSICIAN, 2015, 91 (11) : 788 - 788
  • [24] Achieving glycemic goals in type 2 diabetes
    Bloomgarden, Zachary T.
    DIABETES CARE, 2007, 30 (01) : 174 - 180
  • [25] THE COST-EFFECTIVENESS ANALYSIS OF VIDALGLIPTIN IN TYPE 2 DIABETES IN POLAND
    Walczak, J.
    Nogas, G.
    Gebus, E.
    Pawlik, D.
    Pacocha, K.
    VALUE IN HEALTH, 2009, 12 (07) : A406 - A406
  • [26] Screening for type 2 diabetes mellitus: A cost-effectiveness analysis
    Hoerger, TJ
    Harris, R
    Hicks, KA
    Donahue, K
    Sorensen, S
    Engelgau, M
    ANNALS OF INTERNAL MEDICINE, 2004, 140 (09) : 689 - 699
  • [27] Cost-effectiveness of saxagliptin (Onglyza®) in type 2 diabetes in Sweden
    Granstrom, Ola
    Bergenheim, Klas
    McEwan, Phil
    Sennfalt, Karin
    Henriksson, Martin
    PRIMARY CARE DIABETES, 2012, 6 (02) : 127 - 136
  • [28] COST-EFFECTIVENESS OF LIRAGLUTIDE FOR SUBJECTS WITH TYPE 2 DIABETES IN SPAIN
    Ramirz de Arellano, A.
    Hunt, B.
    Mezquita Raya, P.
    Briones, T.
    Perez, A.
    Valentine, W. J.
    VALUE IN HEALTH, 2014, 17 (03) : A249 - A250
  • [29] COST-EFFECTIVENESS OF NEW ANTIDIABETICS IN TYPE 2 DIABETES: A REVIEW
    Baytar, S.
    Malhan, S.
    VALUE IN HEALTH, 2010, 13 (07) : A292 - A292
  • [30] Cost-Effectiveness of Saxagliptin in Type 2 Diabetes in the United States
    Bergenheim, Klas
    Williams, Setareh A.
    Bergeson, Joette G.
    Stern, Lee
    Sriprasert, Michelle
    DIABETES, 2011, 60 : A629 - A630
12345